The CYP2J2 G-50T polymorphism and myocardial infarction in patients with cardiovascular risk profile

被引:32
|
作者
Boergel, Jan [1 ]
Bulut, Daniel [1 ]
Hanefeld, Christoph [1 ]
Neubauer, Horst [1 ]
Muegge, Andreas [1 ]
Epplen, Joerg T. [2 ]
Holland-Letz, Tim [3 ]
Spiecker, Martin [4 ]
机构
[1] Ruhr Univ Bochum, St Josef Hosp Bergmannsheil, Dept Cardiol, Bochum, Germany
[2] Ruhr Univ Bochum, Dept Human Genet, Bochum, Germany
[3] Ruhr Univ Bochum, Dept Med Informat Biometry & Epidemiol, Bochum, Germany
[4] Marien Hosp, Dept Cardiol, Marl, Germany
关键词
D O I
10.1186/1471-2261-8-41
中图分类号
R5 [内科学];
学科分类号
1002 ; 100201 ;
摘要
Background: Cytochrome P450 (CYP) enzyme 2J2, an epoxygenase predominantly expressed in the heart, metabolises arachidonic acid to biologically active eicosanoids. One of the CYP2J2 products, 11, 12-epoxyeicosatrienoic acid, has several vasoprotective effects. The CYP2J2-G-50T-promotor polymorphism decreases gene expression and is associated with coronary artery disease. This association supports the vascular protective role of CYP-derived eicosanoids in cardiovascular disease. In the present study, we investigated the influence of this polymorphism on survived myocardial infarction in two study groups of patients with on average high cardiovascular risk profile. Methods: The CYP2J2 polymorphism was genotyped in two groups of patients that were collected with the same method of clinical data collection. Data from 512 patients with sleep apnoea (group: OSA) and on average high cardiovascular risk profile and from another 488 patients who were admitted for coronary angiography (CAR-group) were evaluated for a potential correlation of the CYP2J2 polymorphism G-50T and a history of myocardial infarction. The G-50T polymorphism of the CYP2J2 gene was genotyped by allele specific restriction and light cycler analysis. Results: The T-allele of the polymorphism was found in 111 (11.1%; CAR-group: N = 65, 13.3%; OSA: N = 46, 9.0%). 146 patients had a history of myocardial infarction (CAR: N = 120, 24.6%; OSA: N = 26, 5.1%). Cardiovascular risk factors were equally distributed between the different genotypes of the CYP2J2 G-50T polymorphism. In the total group of 1000 individuals, carriers of the T-allele had significantly more myocardial infarctions compared to carriers of the wild type (T/T or G/T: 21.6%; G/G: 13.7%; p = 0.026, odds ratio 1.73, 95%-CI [1.06-2.83]). In the multivariate logistic regression analysis the odds ratio for a history of myocardial infarction in carriers of the T-allele was 1.611, 95%-CI [0.957-2.731] but this trend was not significant (p = 0.073). Conclusion: In presence of other risk factors, the CYP2J2 G-50T failed to show a significant role in the development of myocardial infarction. However, since our result is close to the border of significance, this question should be clarified in larger, prospective studies in the future.
引用
收藏
页数:6
相关论文
共 50 条
  • [31] A NOVEL POLYMORPHISM OF THE CYP2J2 GENE IS ASSOCIATED WITH CORONARY HEART DISEASE IN UYGUR POPULATION IN CHINA
    Fuzhenyan
    Zhu Qing
    Ma Yitong
    HEART, 2013, 99 : E142 - E142
  • [32] Association of CYP2J2 polymorphism with susceptibility to psoriasis in Turkish population: a case-control study
    Hayran, Yildiz
    Alli, Nuran
    Uysal, Pinar Incel
    Candar, Tuba
    ANAIS BRASILEIROS DE DERMATOLOGIA, 2020, 95 (01) : 25 - 31
  • [33] A NOVEL POLYMORPHISM OF THE CYP2J2 GENE IS ASSOCIATED WITH CORONARY HEART DISEASE IN UYGUR POPULATION IN CHINA
    Zhu Qing
    Ma Yitong
    HEART, 2013, 99 : E29 - E30
  • [34] Genetic polymorphism analysis of CYP2J2 drug-metabolizing enzyme in a Chinese Zhuang population
    Zhang, Chan
    Chen, Wanlu
    Li, Qing
    Shi, Xugang
    Xia, Ridong
    Zhang, Ning
    Zhu, Xikai
    Kang, Longli
    Yuan, Dongya
    Luo, Manlin
    Jin, Tianbo
    INTERNATIONAL JOURNAL OF CLINICAL AND EXPERIMENTAL PATHOLOGY, 2016, 9 (10): : 10657 - 10663
  • [35] CYP2J2 and CYP2C8 polymorphisms and coronary heart disease risk:: the Atherosclerosis Risk in Communities (ARIC) study
    Lee, Craig R.
    North, Kari E.
    Bray, Molly S.
    Couper, David J.
    Heiss, Gerardo
    Zeldin, Darryl C.
    PHARMACOGENETICS AND GENOMICS, 2007, 17 (05): : 349 - 358
  • [36] Cytochrome P450 epoxygenase CYP2J2 and the risk of coronary artery disease
    Spiecker, Martin
    Liao, James K.
    TRENDS IN CARDIOVASCULAR MEDICINE, 2006, 16 (06) : 204 - 208
  • [37] Genetic variation in CYP2J2 and risk of coronary heart disease: The atherosclerosis risk in communities (ARIC) study
    Lee, Craig R.
    North, Kari E.
    Bray, Molly S.
    Couper, David J.
    Heiss, Gerardo
    Zeldin, Darryl C.
    CIRCULATION, 2006, 114 (18) : 490 - 490
  • [38] Association between polymorphisms of CYP2J2 and EPHX2 genes and risk of coronary artery disease
    Xu, Yujun
    Ding, Hu
    Peng, Jia
    Cui, Guanglin
    Liu, Lei
    Cianflone, Katherine
    Wang, Dao Wen
    PHARMACOGENETICS AND GENOMICS, 2011, 21 (08): : 489 - 494
  • [39] CYP2C19 Gene Polymorphism in Patients With Myocardial Infarction Who Use Clopidogrel
    Galyavich, A. S.
    Valeeva, D. D.
    Minnetdinov, R. Sh.
    Arkhipova, A. A.
    Akhmetov, I. I.
    Galyavi, R. A.
    KARDIOLOGIYA, 2012, 52 (04) : 20 - 24
  • [40] Evaluation of the aldosterone synthase (CYP11B2) gene polymorphism in patients with myocardial infarction
    Hengstenberg, C
    Holmer, SR
    Mayer, B
    Löwel, H
    Engel, S
    Hense, HW
    Riegger, GAJ
    Schunkert, H
    HYPERTENSION, 2000, 35 (03) : 704 - 709